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Abstract
Prostate cancer is the second leading cause of cancer-related death among the American male
population, and society is in dire need of new approaches to treat this disease. Here we report the
design, synthesis, and biological evaluation of a class of bifunctional small molecules, called
antibody-recruiting molecules targeting prostate-cancer (ARM-Ps), that enhance the recognition of
prostate cancer cells by the human immune system. ARM-P derivatives were designed rationally via
the computational analysis of crystallographic data, and we demonstrate here that these materials are
able to: (1) bind PSMA with high affinity (high pM to low nM), (2) template the formation of ternary
complexes between anti-DNP antibodies, ARM-P, and LNCaP human prostate cancer cells, and (3)
mediate the antibody-dependent killing of LNCaP cells in the presence of human effector cells. This
manuscript describes the application of fundamental chemical principles to the design of a novel
class of molecules with high therapeutic potential. We believe that this general small-molecule-based
strategy could give rise to novel directions in treating cancer and other diseases.
Prostate cancer is the second leading cause of cancer-related death among the American male
population, and it has been predicted that one out of every six American men will develop
prostate cancer during their lifetime.1 Available treatment options, including chemical/surgical
castration, radiation therapy, and chemotherapy, are often ineffective against advanced disease,
and are also associated with severe side effects.2 Thus, new approaches to treat prostate cancer
are highly desirable. To this end, monoclonal antibody therapies have shown promise;2
however no such agent has yet successfully obtained FDA approval for treating prostate cancer.
Further, antibody drugs are limited by severe side effects, lack of oral bioavailabiliy, and high
cost.3 Here we describe a novel technology for prostate cancer treatment that we believe could
address many of the limitations of currently available therapies, and combines advantages of
both small-molecule-based and antibody-based strategies.
david.spiegel@yale.edu.
Supporting Information Available: Detailed experimental procedures and compound characterization. This material is available free
of charge via the Internet at http://pubs.acs.org.
NIH Public Access
Author Manuscript
J Am Chem Soc. Author manuscript; available in PMC 2010 December 2.
Published in final edited form as:
J Am Chem Soc. 2009 December 2; 131(47): 17090–17092. doi:10.1021/ja906844e.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The key component of our approach is what we call antibody-recruiting small molecules
targeting prostate cancer (ARM-Ps). These are bifunctional materials capable of redirecting
antibodies already present in the human bloodstream to prostate cancer cell surfaces, and
increasing their destruction by effector cells of the immune system (Figure 1). As shown,
ARMs are composed of an antibody-binding terminus (ABT), a cell surface binding terminus
(CBT), and a linker region. In this manuscript, it is demonstrated that ternary complexes formed
between ARM-Ps, human prostate cancer cells (LNCaP cells), and antibodies recognizing the
2,4-dinitrophenyl (DNP) group lead to targeted cell-mediated cytotoxicity of LNCaP cells. The
power of this approach derives from the observation that anti-DNP antibodies are already found
in the human bloodstream in a high percentage of the human population,4 and are competent
to mediate target cell killing.5,6 Several approaches have appeared that utilize bifunctional
materials to recruit antibodies to human pathogens,7 but ARM-Ps are the first class of antibody-
recruiting small molecules that target prostate cancer. The general strategy reported herein has
the potential to initiate novel directions in treating cancer and other diseases.
Our first goal in constructing ARM-Ps was to design an appropriate cell-binding terminus
(CBT), and to this end, we chose to target the prostate-specific membrane antigen (PSMA).
PSMA is a cell surface protein that is highly overexpressed on prostate cancer cells versus
normal cells of the prostate, and its expression increases with clinical stage.8 This protein has
been exploited as a target both in prostate cancer imaging9 and in monoclonal antibody therapy
for the disease.10
Several small molecule ligands have been developed that bind PSMA selectively and with high
affinity, including 2-PMPA (1)12 and the glutamate ureas (2, Figure 2C).13 These compounds
competitively inhibit PSMA’s enzymatic activity, and have been successfully modified for
imaging, and targeted drug delivery applications.14 At the outset of our studies, we were
intrigued by observations that 2 could accommodate a wide range of R-groups at C2, including
various alkyl heterocycle substituents, with minimal loss of inhibitory potency.13 We therefore
reasoned that we might be able to incorporate a linker to join the ABT and CBT at this position.
Thus, starting from a crystal structure for the complex of PSMA with 1,15 the corresponding
complex with 2 (R=H) was modeled using the program BOMB (biochemical and organic model
builder).16 Stabilizing interactions are indicated with active site zinc ions, as well as hydrogen
bonding and salt-bridge interactions with Tyr700, Lys699, Arg534, Arg536, and Asn257
(Figure 2A). This model was found subsequently to be consistent with the recently published
co-crystal structure of PSMA in complex with urea-based ligands.17 Next, BOMB was used
to construct complexes of 2 with alternative DNP linking groups. Among plausible designs,
1-butyl-4-alkyl-1,2,3-triazole analogues (e.g., 3–6) were judged promising owing to favorable
electrostatic interactions with Arg463, π-stacking interactions with Tyr700, the orientation of
the linker towards solvent, and ease of synthesis.
To estimate viable linker lengths, ternary complexes (PSMA, ARM-Ps, the Fv region of an
anti-DNP antibody18) were constructed using the program FIRST (Figure 2B).19 Constrained
geometric simulations20 were then performed to assemble the complex with the ABT and CBT
binding sites in close proximity. The modeling suggested that at least 6 oxyethylene units would
be necessary to prevent steric clashes between the two proteins, and that longer linkers might
be preferable to prevent excessive dehydration of the protein-protein interface.
Thus, ARM-Ps 3–6 were synthesized (Figure 2C, called ARM-P4 through ARM-P12, for the
number of oxyethylene units in the linker) and tested for binding to PSMA through a standard
enzymatic inhibition assay.22 This assay measures the ability of designed small molecules to
inhibit PSMA-catalyzed cleavage of the peptide substrate N-acetyl-aspartyl-glutamate
(NAAG). As depicted in Figure 3, compound 3 (ARM-P4) inhibits PSMA with a Ki of 63 pM,
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a value similar to the most potent PSMA-binding small molecule developed to date.17 Although
we anticipated that the flexible PEG linker in 3 could lead to entropic penalties in binding
PSMA, perhaps stabilizing interactions with the triazole, DNP, and/or PEG portions of ARM-
P4 are compensating. Interestingly, compounds 4–6, which contain 6, 8, and 12 oxyethylene
units, exhibited decreased inhibitory potency versus ARM-P4 (3). The origin of the trend is
currently under investigation.
To evaluate the capacity of ARM-P derivatives to template ternary complex formation in a
cellular environment, we performed live-cell flow cytometry assays with PSMA-expressing
LNCaP cells and Alexafluor488 conjugated anti-DNP antibodies. Since the anti-DNP antibody
represented the fluorescent component in these studies, rightward shifts of flow cytometry
histograms indicate increased levels of ternary complex formation. These experiments revealed
an intriguing trend (Figure 4A): although ARM-P4 (3) possessed the highest affinity in PSMA-
binding assays, maximal amounts of ternary complex were formed in the presence of ARM-
P8 (5). These results are consistent with predictions from computational modeling studies
(Figure 2B, see above), which suggest that linker lengths of n=4 and 6 could lead to unfavorable
steric interactions between antibody and PSMA. The relative decrease in ternary complex
formation for ARM-P12 versus ARM-P8 may simply result from the decreased affinity of
ARM-P12 for PSMA, consistent with results in Figure 3.
ARM-P8 was therefore chosen for evaluation in subsequent studies. Flow cytometry
experiments performed in the excess of the competing ligands 2-PMPA or bis-DNP lysine
(Figure 4B), reveal baseline levels of ternary complex. Further, no ternary complex formation
was observed under these conditions using DU145 prostate cancer cells, which lack PSMA.
23 Together, these data confirm that small-molecule-mediated antibody recruitment is
dependent upon binding of ARM-P8 to both PSMA and anti-DNP antibodies. Further,
competition with 2-PMPA and bis-DNP lysine was found to be concentration-dependent
(Figure 4C). The Ki value determined for 2-PMPA in these studies was found to be 5.0 nM,
which is almost identical to that determined in enzymatic assays (2.3 nM).23 This result implies
that ARM-P binding to PSMA does not benefit from increased affinity due to multivalent
presentation.7c,g Fluorescent microscopy experiments (Figure 4D) further confirm flow
cytometry data, and demonstrate localization of the ternary complex to the cell membrane. No
fluorescence was observed in the absence of ARM-P8.23 Endocytosis of fluorescent features
at 37 °C, but not 4 °C, is consistent with reported behavior of PSMA.24
Having established that ARM-P8 possessed optimal linker length in forming ternary
complexes, we tested its ability to induce cell-mediated cytotoxicity of LNCaP prostate cancer
cells. This process is known to take place by way of interactions between Fc-receptors on
cytotoxic effector cells contained in peripheral blood (such as NK cells, macrophages, and
dendritic cells), and the Fc (constant) regions of antibodies.6 Thus, LNCaP cells were combined
with peripheral blood mononuclear cells (PBMCs), anti-DNP antibodies, and ARM-P8, and
cell death was measured using a commercially available calcein-release-assay (Figure 5).25 As
expected (vide infra), ARM-P8 at concentrations up to 30 nM led to enhanced cell killing,
while treatment with ARM-P4 (3) led to no changes in cell viability. The antibody
concentration employed in these experiments is slightly below that found in human serum,4
and lower concentrations were also found to be efficacious (Figure S5). DU145 cells were not
susceptible to ARM-P8 mediated cell killing, and no cytotoxicity was observed in either
LNCaP or DU145 cell lines after treatment with ARM-P8 in the absence of effector PBMCs,
indicating that this compound is not itself cytotoxic (Figure S5).
Notably, the intriguing bell-shaped pattern observed in cell killing measurements with ARM-
P8 has been observed in various situations in which bifunctional ligands template ternary
linkages.26 Such behavior results from the binding dynamics of these systems – at large total
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concentrations of bifunctional small molecule, unbound material competes with the ternary
complex, driving the system toward formation of binary complexes. We view this self-
antagonistic trend in ARM-P8-mediated cytotoxicity experiments as evidence that cell killing
proceeds via reversible formation of a ternary complex. Furthermore, from a clinical
standpoint, such a model reveals a unique advantage associated with this novel class of
bifunctional therapeutics: they are auto-inhibitory, and could serve clinically as the antidote
for their own overdose.
Here we report the structure-based design of a class of prostate cancer-targeted antibody-
recruiting small molecules (ARM-Ps) capable of binding to prostate-specific membrane
antigen with high affinity (pM to nM), and recruiting antibodies to PSMA-expressing cells.
We have also demonstrated that one member of this class, ARM-P8, is capable of inducing
antibody- and PBMC-dependent cytotoxicity at concentrations in the nanomolar range. This
ARM-based strategy could have profound advantages in the treatment of human cancers. Its
auto-inhibitory pharmacology (See Figure 5, above) represents a unique regulatory mechanism
worthy of further study. Also, it exploits pre-existing immune mechanisms, not cytotoxic
compounds, in cell killing and thus could lead to safer cancer therapies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors thank John Hines, Thomas Gniadek, and Jacob Appelbaum for helpful suggestions and experimental
assistance. This work was funded by the National Institutes of Health through the NIH Director’s New Innovator
Award Program (DP22OD002913, DAS), and the National Foundation for Cancer Research (WLJ). JM acknowledges
support from a Marie Curie International Fellowship from the European Commission (FP7-PEOPLE-2008-4-1-IOF,
234796-PPIdesign).
References
1. American Cancer Society. Cancer Facts and Figures 2009. 2009. Available online
2. Olson WC, Heston WD, Rajasekaran AK. Rev. Recent Clin. Trials 2007;2:182–190. [PubMed:
18474004]
3. Allen TM. Nat. Rev. Cancer 2002;2:750–763. [PubMed: 12360278]
4. Antibodies recognizing the 2,4-dinitrophenyl (DNP) epitope have been estimated to constitute 1% of
circulating IgM (approx. 10 µg/mL in human serum) and 0.8% of circulating IgG (approx. 40–120
µg/mL in human serum). See (a) Karjalainen K, Makela O. Eur. J. Immunol 1976;6:88–93. [PubMed:
964298] (b) Farah FS. Immunology 1973;25:217–226. [PubMed: 4733801] and (c) Rowe, DS.;
Anderson, SG.; Skegg, J. Immunoglobulins. Merler, E., editor. National Academy of Sciences Press;
1970. p. 361 The prevalence of anti-DNP antibodies has been estimated at between 18–90% of humans
(see (d) Ortega E, Kostovetzky M, Larralde C. Mol. Immunol 1984;21:883–888. [PubMed: 6504050]
and (e) Jormalainen S, Makela O. Eur. J. Immunol 1971;1:471–478. [PubMed: 4947912] )
5. Muller-Eberhard HJ. Annu. Rev. Biochem 1988;57:321–347. [PubMed: 3052276]
6. Hale G, Clark M, Waldmann H. J. Immunol 1985;134:3056–3061. [PubMed: 3980990]
7. For antibacterial approaches, see: (a) Bertozzi CR, Bednarski MD. J. Am. Chem. Soc 1992;114:5543–
5546. (b) Bertozzi CR, Bednarski MD. J. Am. Chem. Soc 1992;114:2242–2245. (c) Krishnamurthy
V, Quinton L, Estroff L, Metallo S, Isaacs J, Mizgerd J, Whitesides G. Biomaterials 2006:12. For anti-
HIV approaches, see: (d) Shokat KM, Schultz PG. J. Am. Chem. Soc 1991;113:1861–1862. (e) Naicker
KP, Li H, Heredia A, Song H, Wang L. Org. and Biomolec. Chem 2004;2:660–664. (f) Perdomo MF,
Levi M, llberg MS, Vahlne A. Proc. Natl. Acad. Sci. U.S.A 2008:6. [PubMed: 19118201] For anti-
cancer approaches, see: (g) Carlson C, Mowery P, Owen R, Dykhuizen EC, Kiessling L. ACS Chem.
Biol 2007;2:119–127. [PubMed: 17291050] (h) Popkov M, Gonzalez B, Sinha S, Barbas C. Proc. Natl.
Murelli et al. Page 4
J Am Chem Soc. Author manuscript; available in PMC 2010 December 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Acad. Sci. U.S.A 2009;106:4378–4383. [PubMed: 19255430] and (i) Lu Y, You F, Vlahov I, Westrick
E, Fan M, Low PS, Leamon CP. Mol. Pharm 2007;4:695–706. [PubMed: 17784727]
8. Holmes EH, Greene TG, Tino WT, Boynton AL, Aldape HC, Misrock SL, Murphy GP. Prostate Suppl
1996;7:25–29. [PubMed: 8950359]
9. Mohammed AA, Shergill IS, Vandal MT, Gujral SS. Expert Rev. Mol. Diagn 2007;7:345–349.
[PubMed: 17620043]
10. Slovin SF. Expert Opin. Ther. Targets 2005;9:561–570. [PubMed: 15948673]
11. Humphrey W, Dalke A, Schulten K. J. Mol. Graph 1996;14:33–38. 27–28. [PubMed: 8744570]
12. Slusher BS, et al. Nat. Med 1999;5:1396–1402. [PubMed: 10581082]
13. Kozikowski AP, Zhang J, Nan F, Petukhov PA, Grajkowska E, Wroblewski JT, Yamamoto T, Bzdega
T, Wroblewska B, Neale JH. J. Med. Chem 2004;47:1729–1738. [PubMed: 15027864]
14. Humblet V, Misra P, Bhushan KR, Nasr K, Ko Y, Tsukamoto T, Pannier N, Frangioni JV, Maison
W. J. Med. Chem 2009;52:544–550. [PubMed: 19108655]
15. Barinka C, Rovenska M, Mlcochova P, Hlouchova K, Plechanovova A, Majer P, Tsukamoto T,
Slusher BS, Konvalinka J, Lubkowski J. J. Med. Chem 2007;50:3267–3273. [PubMed: 17567119]
16. Jorgensen WL. Acc. Chem. Res 2009;42:724–733. [PubMed: 19317443]
17. Barinka C, Byun Y, Dusich CL, Banerjee SR, Chen Y, Castanares M, Kozikowski AP, Mease RC,
Pomper MG, Lubkowski J. J. Med. Chem 2008;51:7737–7743. [PubMed: 19053759]
18. James LC, Roversi P, Tawfik DS. Science 2003;299:1362–1367. [PubMed: 12610298]
19. Jacobs DJ, Rader AJ, Kuhn LA, Thorpe MF. Proteins 2001;44:150–165. [PubMed: 11391777]
20. Wells S, Menor S, Hespenheide B, Thorpe MF. Phys. Biol 2005;2:S127–S136. [PubMed: 16280618]
21. Cheng Y, Prusoff WH. Biochem. Pharmacol 1973;22:3099–3108. [PubMed: 4202581]
22. Natarajan A, Du W, Xiong C-Y, DeNardo GL, DeNardo SJ, Gervay-Hague J. Chem. Commun
2007:695–697.
23. Details of these experiments can be found in the Supporting Information.
24. Anilkumar G, Barwe SP, Christiansen JJ, Rajasekaran SA, Kohn DB, Rajasekaran AK. Microvasc.
Res 2006;72:54–61. [PubMed: 16713605]
25. Neri S, Mariani E, Meneghetti A, Cattini L, Facchini A. Clin. Diagn. Lab. Immunol 2001;8:1131–
1135. [PubMed: 11687452]
26. Mack ET, Perez-Castillejos R, Suo Z, Whitesides GM. Anal. Chem 2008;80:5550–5555. [PubMed:
18543951] and references contained therein.
Murelli et al. Page 5
J Am Chem Soc. Author manuscript; available in PMC 2010 December 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
Schematic depiction of the reported approach to prostate cancer targeting. An antibody-
recruiting small molecule (ARM) binds the cell-surface prostate cancer marker prostate-
specific membrane antigen (PSMA), thus recruiting antibodies to these cells for recognition
and targeted killing by the immune system. Bifunctional ARMs are composed of an antibody
binding terminus (ABT), a linker region, and a cell-binding terminus (CBT).
Murelli et al. Page 6
J Am Chem Soc. Author manuscript; available in PMC 2010 December 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Structure-based design studies. (A) Modeled complex illustrating the design of a CBT for use
in ARM-Ps. (B) Structural model of the ternary complex between the Fv region of an anti-
DNP antibody, ARM-P, and the PSMA dimer. (C) Known PSMA-binding small molecules
and structures of ARM-P derivatives utilized in this study. Figures 2A and B were created with
the program VMD.11
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Figure 3.
Representative PSMA inhibition curves for ARM-Ps. Ki values were calculated from measured
IC50 and KM values through the Cheng-Prusoff equation21 and are reported as the average of
3 runs ± standard deviation.
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Figure 4.
Evaluating ternary complex formation. (A) and (B) Representative traces from flow cytometry
experiments. (C) Dose dependence of competitor concentration on ternary complex. (D)
Epifluorescence (Fluor) and brightfield (BF) microscopy experiments performed in the
presence of ARM-P8 at 37 °C and 4 °C.
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Figure 5.
Antibody-Dependent Cellular Cytotoxicity (ADCC) Assays. LNCaP (PSMA-positive) and
DU145 (PSMA-negative) cells were treated with the ARM-P derivatives at the indicated
concentrations, and cell death was measured with and without exposure to anti-DNP antibody
(Ab, 24 µg/mL) and peripheral blood mononuclear cells (PBMC). Points represent the average
of 4 measurements ± standard deviation. All depicted trends were observed on at least three
separate occasions.
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